GILDDiagnostics•businesswire•
New Analysis Shows Corrected T1 (cT1) Is the Most Appropriate Diagnosis and Monitoring Tool for Widespread Adoption of Resmetirom Treatment in the United States
Sentiment:Positive (70)
Summary
(NASDAQ:GILD) WASHINGTON--(BUSINESS WIRE)-- #LiverMultiScan--Economic analysis shows LiverMultiScan is the most appropriate diagnosis and monitoring tool for scalable adoption of resmetirom in the United States.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by businesswire